Our life science clients aim to maximise the potential of new and existing technologies; a specialism that demands an equally specialist legal adviser. That’s exactly what our team looks to provide, offering significant sector experience in pharmaceutical, healthcare and biotech.

Our clients represent all aspects of the life sciences community, including university spin-outs, entrepreneurs and multi-national corporations operating across drug discovery and clinical research to contract manufacturing and product development. The technologies our clients work with include pharmaceutical products, diagnostic tests and medical and dental devices at all stages of development.

  • The team at Shepherd and Wedderburn get it. They have a full grasp of our business and what we are trying to achieve.


Aircraft Medical Limited
Acted for Aircraft Medical Ltd in its $110m sale to Covidien Group S.a.r.l. (part of Medtronic group) by way of offer
Biocompatibles International plc
Acted for Biocompatibles International, a Main Market listed medical technology company valued at £177m, on its recommended acquisition by BTG plc
Centeo Biosciences Limited
Advised Centeo Biosciences in relation to its formation, subsequent rounds of funding and commercial agreements to assist the launch and development of its life sciences products globally
Advising TEVA on a range of Competition Authority enforcement cases at OFT and European Commission levels
Scottish National Blood Transfusion Service
Advised the Scottish National Blood Transfusion Service on the spin out of Alba Bioscience, a major bio-manufacturing organisation, including advice on identification of required IP and cell lines, technology transfer and supply agreements
ProStrakan Group plc
Reviewed and advised on certain template agreements used by ProStrakan in its clinical trials. This included ProStrakan's template Investifator Sponsored Clinical Trial Agreement for use in the EU
Phosphagenics Limited
Advising Phosphagenics Limited for possible UK and EU consumer and cosmetic product regulation issues (possible borderline product) on its beauty product packaging and insert statements prior to launch in a major pharmaceutical chain across the UK
Nexus Oncology Limited
Acted for the shareholders of Nexus Oncology Limited in connection with the sale to Ockham Development Group (Holdings) UK Limited